Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03414294




Registration number
NCT03414294
Ethics application status
Date submitted
9/01/2018
Date registered
29/01/2018
Date last updated
28/01/2020

Titles & IDs
Public title
A Study to Evaluate the Safety of K-755 in Healthy Volunteers
Scientific title
A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study to Investigate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of K-755 in Healthy Adult Volunteers
Secondary ID [1] 0 0
K-755-1.01AU
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - K-755 Part A (SAD)
Treatment: Drugs - Placebo Part A (SAD)
Treatment: Drugs - K-755 Part B (MAD)
Treatment: Drugs - Placebo Part B (MAD)
Treatment: Drugs - K-755 Part C (FE)
Treatment: Drugs - K-755 Part D (FE)
Treatment: Drugs - K-755 Part E (MAD)
Treatment: Drugs - Placebo Part E (MAD)

Experimental: K-755 Part A (SAD) -

Placebo comparator: Placebo Part A (SAD) -

Experimental: K-755 Part B (MAD) -

Placebo comparator: Placebo Part B (MAD) -

Experimental: K-755 Part C (FE) -

Experimental: K-755 Part D (FE) -

Experimental: K-755 Part E (MAD) -

Placebo comparator: Placebo Part E (MAD) -


Treatment: Drugs: K-755 Part A (SAD)
Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.

Treatment: Drugs: Placebo Part A (SAD)
Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.

Treatment: Drugs: K-755 Part B (MAD)
Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.

Treatment: Drugs: Placebo Part B (MAD)
Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.

Treatment: Drugs: K-755 Part C (FE)
Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.

Treatment: Drugs: K-755 Part D (FE)
Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.

Treatment: Drugs: K-755 Part E (MAD)
Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.

Treatment: Drugs: Placebo Part E (MAD)
Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A, B, C, D and E: Incidence and severity of Adverse Events
Timepoint [1] 0 0
Up to 28 days after last administration
Primary outcome [2] 0 0
Part A, B, C, D and E: Number of subjects with clinical laboratory test abnormalities
Timepoint [2] 0 0
Up to 28 days after last administration
Primary outcome [3] 0 0
Part A, B, C, D and E: Number of subjects with vital signs abnormalities
Timepoint [3] 0 0
Up to 28 days after last administration
Primary outcome [4] 0 0
Part A, B, C, D and E: Number of subjects with clinically significant change in body weight
Timepoint [4] 0 0
Up to 28 days after last administration
Primary outcome [5] 0 0
Part A, B, C, D and E: Number of subjects with abnormal findings in physical examinations
Timepoint [5] 0 0
Up to 28 days after last administration
Secondary outcome [1] 0 0
Part A: AUC0-inf of K-755
Timepoint [1] 0 0
Up to 28 days after single administration
Secondary outcome [2] 0 0
Part A: AUC0-tlast of K-755
Timepoint [2] 0 0
Up to 28 days after single administration
Secondary outcome [3] 0 0
Part A: Cmax of K-755
Timepoint [3] 0 0
Up to 28 days after single administration
Secondary outcome [4] 0 0
Part A: Tmax of K-755
Timepoint [4] 0 0
Up to 28 days after single administration
Secondary outcome [5] 0 0
Part A: t1/2 of K-755
Timepoint [5] 0 0
Up to 28 days after single administration
Secondary outcome [6] 0 0
Part B: AUC0-t of K-755
Timepoint [6] 0 0
Up to 28 days after repeated administration
Secondary outcome [7] 0 0
Part B: Cmax of K-755
Timepoint [7] 0 0
Up to 28 days after repeated administration
Secondary outcome [8] 0 0
Part B: Tmax of K-755
Timepoint [8] 0 0
Up to 28 days after repeated administration
Secondary outcome [9] 0 0
Part B: t1/2 of K-755
Timepoint [9] 0 0
Up to 28 days after repeated administration
Secondary outcome [10] 0 0
Part C: AUC0-inf of K-755
Timepoint [10] 0 0
Up to 14 days after single administration
Secondary outcome [11] 0 0
Part C: AUC0-tlast of K-755
Timepoint [11] 0 0
Up to 14 days after single administration
Secondary outcome [12] 0 0
Part C: Cmax of K-755
Timepoint [12] 0 0
Up to 14 days after single administration
Secondary outcome [13] 0 0
Part C: Tmax of K-755
Timepoint [13] 0 0
Up to 14 days after single administration
Secondary outcome [14] 0 0
Part C: t1/2 of K-755
Timepoint [14] 0 0
Up to 14 days after single administration
Secondary outcome [15] 0 0
Part D: AUC0-inf of K-755
Timepoint [15] 0 0
Up to 14 days after single administration
Secondary outcome [16] 0 0
Part D: AUC0-tlast of K-755
Timepoint [16] 0 0
Up to 14 days after single administration
Secondary outcome [17] 0 0
Part D: Cmax of K-755
Timepoint [17] 0 0
Up to 14 days after single administration
Secondary outcome [18] 0 0
Part D: Tmax of K-755
Timepoint [18] 0 0
Up to 14 days after single administration
Secondary outcome [19] 0 0
Part D: t1/2 of K-755
Timepoint [19] 0 0
Up to 14 days after single administration
Secondary outcome [20] 0 0
Part E: AUC0-t of K-755
Timepoint [20] 0 0
Up to 14 days after single administration
Secondary outcome [21] 0 0
Part E: Cmax of K-755
Timepoint [21] 0 0
Up to 14 days after single administration
Secondary outcome [22] 0 0
Part E: Tmax of K-755
Timepoint [22] 0 0
Up to 14 days after single administration
Secondary outcome [23] 0 0
Part E: t1/2 of K-755
Timepoint [23] 0 0
Up to 14 days after single administration

Eligibility
Key inclusion criteria
1. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
2. Males or females, of any race, between 18 and 45 years of age.
3. Body mass index (BMI) between 18.0 and 28.0 kg/m2.
4. Hematology, clinical chemistry, and urinalysis test results within the reference ranges or showing no clinically relevant deviations, as judged by the Investigator.
5. No clinically significant abnormalities on the basis of medical history, physical examination findings, and vital signs.
6. All females must have a negative serum pregnancy test.
7. Able and willing to comply with the protocol and study procedures.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Female subject who are pregnant or breastfeeding.
2. Subject with presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.
3. Subject with any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of K-755.
4. Subject with presence of an active malignancy or within the past 5 years a malignancy of any type, other than basal cell carcinoma of the skin.
5. Subject has a history of type 1 hypersensitivity to any medication and/or clinically relevant food allergies.
6. Subject has a history of drug addiction.
7. Subject has a positive screen for drugs of abuse, cotinine or alcohol.
8. Subject has a history of regular alcohol consumption within 6 months of the study.
9. Subject has smoked tobacco within 6 months prior to Check-in, or has used non-inhaled tobacco- or nicotine-containing products within 3 months prior to Check-in.
10. Subject has used prescription or over-the-counter medications, dietary/nutritional supplements (except paracetamol or vitamin supplements)
11. Subject has used steroid medications (oral, inhaled, parenteral, or topical) within 30 days or 5 half-lives (whichever is longer) before study drug administration.
12. Subject has participated in an investigational drug study within 30 days or 5 half-lives (whichever is longer) before study drug administration.
13. Subject has a positive screen for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 and 2 antigens/antibodies.
14. Subject has had a clinically significant acute illness within 4 weeks or other illness within 5 days before the first study drug administration.
15. Subject or a family member of the subject is a member of the professional or ancillary personnel working at the investigative site involved in the study.
16. Not suitable for entry into the study in the opinion of the Investigator.
17. Receipt of blood products within 2 months prior to Check-in.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/02/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/11/2019
Sample size
Target
Accrual to date
Final
121
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX, Clinical Research Pty Ltd - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Kowa Company, Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03414294